Home LiteratureArticle Details
PMID: 41029774 Published · epublish English

Rare single PML::RARA fusion transcript from insertion on derivative chromosome 17 in acute promyelocytic leukemia.

Molecular cytogenetics ·Vol. 18 ·No. 1 ·2025-09-30

Yang P, Cassidy D, Amador C, Venugopal S

Abstract

Over 90% of patients with acute promyelocytic leukemia (APL) harbor the typical translocation characterized by the dual fusion of PML::RARA and RARA::PML transcripts. Here, we report a case with a single fusion of PML::RARA formed on der(17), without the RARA::PML fusion, and the patient responded well to all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) therapy. To our knowledge, this represents only the fourth reported case of this type. Our findings indicate that the PML::RARA fusion is the primary driver of APL leukemogenesis and the main therapeutic target for ATRA and ATO, suggesting that the RARA::PML transcript may not be essential for APL development.

Keywords
PML::RARA and RARA::PML transcripts Acute promyelocytic leukemia (APL) All-trans-retinoic acid (ATRA) Arsenic trioxide (ATO) therapy
Article Info
Journal
Molecular cytogenetics
Abbr.
Mol Cytogenet
ISSN
1755-8166
Corresponding email
Published
2025-09-30
Language
English
Country/Region
England
NLM ID
101317942
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]